Maven Securities LTD Altimmune, Inc. Transaction History

Maven Securities LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $33,568 - $56,095	-3,408 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $43,315 - $82,848	3,408 New	3,408 $48,000
Q4 2020 Feb 12, 2021	SELL	$7.84 - $14.22 $196,000 - $355,500	-25,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$9.93 - $33.26 $248,250 - $831,500	25,000 New	25,000 $325,000

192

42.2M

1.05M

582K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $305M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.